(NYSE:MYL) tablet ultram announced today that the U. Shipments are expected to tablet ultram begin immediately. Includes Extended-Release and Orally Disintegrating Tablet Formulations; — Launch Under Ultram(R) Brand Names Planned for Early 2006; — Biovail Receives $60-Million Supply Prepayment; — Biovail’s Supply Price Reaches 37. 5% of Partner’s Net Selling Price Biovail Corporation (NYSE:BVF)(TSX:BVF) announced today that a subsidiary has entered into a supply agreement with Ortho-McNeil, Inc. , a Johnson & Johnson company, for the marketing and distribution of a once-daily, extended-release (ER) formulation and an orally disintegrating (ODT), immediate-release formulation of tramadol hydrochloride in the United States and Puerto Rico. Forward-looking statements are identified by words such as believe, anticipate, expect, intend, plan, will, may and other similar expressions. Eon Labs is a generic pharmaceutical company specializing in developing, licensing, manufacturing, selling and distributing a broad range of prescription pharmaceutical products. A recent study of the American population concluded that nearly 40% of adults have experienced problems with swallowing tablets — and a significant proportion of those fail to comply properly with their prescribed and ongoing dosage. Ultram(R) ODT, which is indicated for moderate to moderately severe pain, received tablet ultram fda approval on May 5, 2005, and will be available in a 50mg dosage strength. Tramadol is tablet ultram one of a number of analgesics, which are among the most effective medications for the treatment of chronic pain. Upon closing tablet ultram of the transaction, Ortho-McNeil will pay to Biovail a supply prepayment of $60 million to be credited against product purchases of Ultram(R) ER. Subject to FDA approval, Ralivia(TM) FlashDose(R) will be available in 50mg, tablets by prescription only. Johnson Pharmaceutical Research Institute’s Ultram(R) Tablets which is indicated for the management of moderate to moderately severe pain. To the extent any statements made in this release contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Patent and Trademark Office that are tablet ultram expected to be issued, and listed in the U. Patients will benefit from the convenience of this FlashDose form — particularly those who have difficulty swallowing tablets or may do not always tablet ultram have access to water. For further information, please contact Ken Howling at 905-286-3000 or send inquiries to ir@biovail. Conditions such as post procedural pain Tablet ultram with swelling, associated with swallowing impairment, that require acute analgesic treatment — will benefit from the immediate orally dissolving tablet form. Food and Drug Administration has granted approvable status for Tramadol Hydrochloride Tablets, 50 mg. In exchange, Ortho-McNeil has waived the three-year statutory exclusivity with respect to Purdue’s Tablet ultram partner, Labopharm Inc. ’s formulation. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks and uncertainties that could cause the Company’s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements.